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Abstract
Objective To report on a 6-year experience with wide-field
digital imaging based telemedicine (WFDI telemedicine) to
reduce the risk for blindness from retinopathy of prematurity
(ROP).
Methods Wide-angle digital fundus cameras (RetCam 120,
Massie Lab, Pleasanton, CA, USA) were installed in five
neonatal intensive care units (NICUs) in Germany. All
prematures at risk were screened with WFDI, and the local
ophthalmologists were asked to continue binocular indirect
ophthalmoscopy (BIO) according to the German guidelines.
Image data were coded and transferred to the Reading
Centre in Regensburg. Image evaluation and additional BIO
of infants with suspected treatment-requiring ROP (STR-
ROP i.e. threshold ROP zone II, prethreshold ROP zone I
(type-1 ROP according to ETROP), and ROP possibly
requiring treatment but not reliably classifiable from the
images) were performed by paediatric ophthalmologists at
the Reading Centre. ROP was classified following ICROP,
ETROP, and revised ICROP criteria. Outcome measures
were incidence of clinically relevant ROP (CR-ROP, i.e.
any ROP up to mid-peripheral zone III, ≤ stage 3+),
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Mainz, Germanysensitivity to detect STR-ROP, and positive predictive value
to detect treatment-requiring ROP (TR-ROP).
Results In total, 1,222 prematures at risk were screened (mean
BW 1395 g, SD ±507 g; mean GA 30 wks, SD ±3 wks). The
overallincidenceofCR-ROPwas27.6%(71.8%mild=stage1
to 3 without plus disease, 15.7% prethreshold=type-1 ROP
according to ETROP, 12.5% threshold according to ICROP).
Zone I disease was present in 3.3%, zone II disease in 76.5%,
andzoneIIIdiseasein20.2%.AccordingtoETROP,95infants
were type-1 or type-2 ROP; 67.4% type-1 ROP, and 32.6%
type-2 ROP. Of all 1,222 infants, 3.5% received treatment.
Following ETROP (not applied in the study), 5.3% would
have been treated. The sensitivity for detecting STR-ROP was
100%, and the positive predictive value for TR-ROP 82.4%
(28/34) at the time of the firstreferral (28 infants, ≤ stage 3+ in
zone I or II).
Conclusion All TR-ROP was detected in time, showing the
potential of our telemedical screening program. The overall
incidence of CR-ROP was comparable to ROP incidences
reported in other West European countries.
Keywords Retinopathyofprematurity (ROP).
Wide-field digitalimaging(WFDI).RetCam120.
Telemedicine.Sensitivity.Positivepredictivevalue
Introduction
Retinopathy of prematurity (ROP) is a potentially blinding
disease that occurs in premature infants, and affects the
postnatal maturation of the retinal blood vessels. Many
significant risk factors have been identified, including
various growth factors [1–13]. The proportion of childhood
blindness caused by ROP now varies from 8% in high-
income countries to 40% in middle-income countries, and
up to 60% in some regions [14, 15].
In 1988, the “Cryotherapy for ROP” study showed
that cryotherapy at threshold disease (stage 3+ in zone I
or II, extraretinal proliferations in 5 contiguous or 8 clock
hours in total according to ICROP [16]) halved the
incidence of retinal detachment and, hence, adverse
outcome. If left untreated, as many as 50% of the children
had an unfavourable outcome [17]. Presently, the preferred
treatment modality of threshold ROP is laser photocoag-
ulation, which decreases the risk of retinal detachment to
only a few percent [18, 19]. In high-income countries,
today about 5% of infants with a birth weight below
1 2 5 0gd e v e l o pt h r e s h o l dd i s e a s e[ 20]. Timing appears
crucial in terms of treatment success. Once threshold
disease is diagnosed, delay in treatment has the risk of
leading to more severe ROP, i.e. “suprathreshold disease”,
and therefore worsens the prognosis [21]. Following the
more recent Early Treatment of ROP (ETROP) study [22],
the criteria and indications for treatment of ROP, partic-
ularly the optimum time for treatment, are under dis-
cussion in many countries. According to ETROP, i.e.
earlier treatment of type-1 ROP, a better overall ROP
outcome is advocated [23].
Expert screening by paediatric ophthalmologists or retina
specialists for repeated exams to detect treatment-requiring
disease according to the evolving definitions is crucial.
Such expert screening is not always available, although
detailed screening guidelines have been provided in various
countries and updated recently [24–30]. In Germany, ROP
screening in the NICUs is frequently provided by general
ophthalmologists with different degrees of experience with
the disease. This is due to the fact that there are at least four
times more NICUs than university sites where treatment is
usually performed. A typical German NICU has 30–60
preterm babies at risk for ROP per year. With the incidence
of threshold disease of about 5% in babies with a birth
weight below 1250 g [31], each NICU will have, on
average, two to three preterm babies at threshold per year
(with spontaneous regression in 50%). Hence, the consult-
ing ophthalmologist—sometimes there are several per
NICU—may not gain sufficient experience in evaluating
the disease. In Germany, direct pension costs for a blind
person (independent of their income) are about 300,000 €
based on the current rates and calculated for a period of
50 years. They do not include specific costs for education
of the blind and specialised equipment for work. Conse-
quently, even a few failed screenings or treatments present a
compelling economic reason to support screening and
treatment programs when multiplied by the high cost of
failure.
Telemedicine combined with WFDI offers the opportu-
nity for improved ROP screening by expert evaluation of
the images independent of the screening site. The
RetCam120, a retinal wide-field digital imaging system,
allows documentation of large parts of the retina of the alert
infant within minutes. Several studies [32–45], have now
evaluated the value of WFDI in screening for ROP. In our
prospective field study we have used, since 2001, the
RetCam120 in five Bavarian NICUs for ROP screening of
infants at risk scheduled according to the German national
guidelines. Four of these NICUs were peripheral sites, with
ROP screening performed by general ophthalmologists. All
images were transferred to the Reading Centre at the
University of Regensburg for evaluation. In a subset of
infants, both WFDI and binocular indirect ophthalmoscopy
BIO were performed by masked examiners. For all other
infants, the local ophthalmologists were asked to continue
BIO as requested by the German guidelines, but in fact did
use BIO at their discretion. Our program was targeted at
detection of clinically relevant ROP (CR-ROP, i.e. any
ROP up to mid-peripheral zone III) with WFDI and
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and to identify suspected treatment-requiring ROP (STR-
ROP, definition see below) and thereby ideally eliminate
late referrals. Our program was not targeted at reduction of
ophthalmic examinations [46].
Material and methods
Patients
The study followed the Tenets of the Declaration of
Helsinki (revised version, 1989) and was approved by the
Ethics Committee of the University of Regensburg (00/
190). Informed consent was obtained from all parents
participating in the study.
In February 2001, RetCam120s were installed in five
NICUs in East Bavaria covering a distance of about
200 km, and every RetCam120 user at that time received
instruction in the use of the instrument from an ophthalmic
photographer experienced in the use of the RetCam (Leslie
MacKeen, Hospital for Sick Children, Toronto, Canada).
Starting from that date, all prematures at risk were
examined with the RetCam120 following the German
screening guidelines as to timing of examinations, gesta-
tional age (GA), and birth weight (BW) (Table 1)[ 29]. At
the same time, all participants were asked to continue
conventional screening with BIO.
Examination protocol
Imaging was performed by general ophthalmologists in
the four peripheral NICUs, and by paediatric ophthal-
mologists of the Reading Centre in the NICU in
Regensburg. The ophthalmologists were directed to begin
their examinations at a chronological age (CA) of 36–
42 days, but not before a postmenstrual age (PMA) of
31 weeks (Table 1).
In the peripheral NICUs, only one examiner at the time did
the examinations. Therefore, an objective comparison of BIO
and WFDI did not appear feasible there. However, all
examiners were instructed to inform the Reading Centre in
caseofdiscrepancies oftheir estimationofROP withBIOand
the results of image evaluation at the Reading Centre.
In 2002 and 2003, in a subset of 63 consecutive
examinations (41 infants) WFDI was performed in the
NICU of the Department of Paediatrics in Regensburg, by a
senior resident, and in parallel conventional BIO by a
paediatric ophthalmologist highly experienced with all
stages of acute ROP (H.E.). Both examiners classified their
findings from either WFDI or BIO, without knowing the
result obtained with the alternative method. The images
were read again in 2008 by the senior investigator (B.L.)
who was masked as to the BIO results.
Examinations were performed after timely administra-
tion of atropine 0.1% (custom-made) and phenylephrine
2% (Neosynephrin-POS® 2%) eye drops for complete
mydriasis, and oxybuprocain (Benoxinat®) eye drops for
local anaesthesia of the cornea and conjunctiva (in the
authors´experience, atropine 0.1% is particularly useful
for obtaining good mydriasis over a period of several
hours, which eliminates the problem of small pupils if
the examination was not done at the scheduled hour). A
sterile wire lid speculum (Barraquer for premature
infants, Geuder, Heidelberg, Germany) was used to keep
the eyelids open, as this speculum is the least space-
consuming, and therefore allows good imaging even in
the smallest infants.
The ophthalmologists were instructed to take six
images per eye with the ROP lens that visualizes 130°:
five images of the retina of each eye in a contact
procedure (one posterior pole image and four more
peripheral images to cover most of the retina), and one
non-contact image of the anterior part of the eye for
evaluating an eventual hyperaemia of the iris and
persistent tunica vasculosa lentis as a sign of acute
ROP (from January 2002). During the course of the
study, it became clear that eight images from the
peripheral retina were better suited to imaging the whole
circumference. This is now the recommended standard
set (Fig. 1). Follow-up examinations were scheduled by
the Reading Centre according to the pathology seen and
following the German guidelines [29], i.e. weekly in the
case of acute ROP in zone I and II if not yet considered
STR-ROP, and every 2 weeks in the absence of ROP but
still incomplete vascularisation, in case of mild zone III
disease, or in the case of beginning regression of any ROP.
Therapy, if required, was performed on site or at the
Reading Centre, according to availability of prolonged
anaesthesia in the peripheral NICUs. The treatment
decision was always based on an additional BIO exam
by a specialist at the Reading Centre (senior investigator
B.L., or an experienced fellow) once STR-ROP had been
diagnosed. STR-ROP was defined as threshold ROP in
zone II, or prethreshold in zone I = type-1 ROP, or
Table 1 German guidelines for screening for acute ROP [29]*
All babies with a GA<32 wks and/or a BW<1,501 g
Babies with a GA<36 wks and artificial oxygen
ventilation for>3 days.
First examination 36 to 42 days PNA, not before 31 wks PMA
GA gestational age, BW birth weight, PNA postnatal age, PMA
postmenstrual age
*The German Guidelines have been revised recently [30]. They have
remained unchanged for the parameters given in the table
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reliably classified from the images. The main reasons for
classification issues were incomplete imaging of the whole
circumference and/or doubts as to the degree of extra-
retinal neovascularisation. WFDI was continued until
vascularisation was estimated to be complete i.e. when
retinal vessels were seen in mid-peripheral zone III, or any
ROP had regressed spontaneously or STR-ROP had
developed. The extreme periphery, i.e. the ora serrata,
was not imaged with WFDI.
Reading of digitized images
Images from the NICU in Regensburg were evaluated by
paediatric ophthalmologists experienced in reading the
images, and in the case of any pathology also by the senior
investigator (B.L.).
Image data received from the RetCam120 examinations
outside Regensburg were sent via ISDN (phone line) to the
Reading Centre without any personal data to assure data
safety. The reader was also blinded as to the result of the
exam in the peripheral NICU. To assign the images to the
respective infants, a coding system was used consisting of
8 digits (Fig. 2). Personal and paediatric data of the infants
were sent anonymously via email or fax to the Reading
Centre using the same code. The images were evaluated by
experienced paediatric ophthalmologists the same day or
the day after, and in the case of any pathology also by the
senior investigator (B.L.). These evaluations and also
recommendations as to control examinations onsite or at
the Reading Centre were sent back via email to the referring
NICU.
Complete imaging with the technology available today
is not feasible in all instances. This does not represent a
real drawback, as the important issue in the context of
screening is to determine whether there is indication of
either immature retina or any pathology that may progress
to treatment-requiring ROP, both warranting follow-up
examinations. To overcome the present limitations and yet
get the necessary information, assessment of the images
included evaluation of: (1) presence of dilated vessels of a
persistent tunica vasculosa lentis and/or iris hyperaemia,
(2) extent of visible retinal vascularisation, (3) shape and
diameter of retinal vessels at the posterior pole, i.e.
vasoconstriction or plus disease, (4) shape, degree of
arborisation and diameter of retinal vessels in the
peripheral images or at the border of clear visibility, and
(5) completeness of imaging as to zone and clock hours.
These additional factors were used for definitive classifi-
cation and to schedule follow-up examinations or eventu-
ally refer infants for BIO because of STR-ROP.
Fig. 1 Standard image set and view of camera (GA 26weeks, BW
710g) ROP 3+, central zone 2. Iris hyperemia and some dilated
remnants of the tunica vasculosa lentis (top left). Shown are
RetCam120 images of the left eye. Bottom left panel shows the
camera in non-contact mode to visualize the anterior segment (from
[54])
Fig. 2 Example of coding system to ensure data security in the
Telemedicine Project. This child has been first examined in 2001 (01)
in the NICU in Deggendorf (d) as the 3rd child examined that year at
the NICU in Deggendorf (003). The last two digits 01 indicate that
this was the first examination of this child
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Demographic data
From 2/2001 to 12/2006, 2,444 eyes of 1,222 preterm
babies were examined. Of these, 913 infants were examined
in the four NICUs outside Regensburg, and 309 were
patients of the NICU in Regensburg. Babies with a
gestational age (GA)>32 completed gestational weeks had
a birth weight (BW)≤1500 g; babies with a BW>1500 g
did not have 32 completed gestational weeks. In addition,
there were a few preterm babies (GA<37 completed
gestational weeks), who had received oxygen for more
than 3 days and were therefore screened for ROP. Detailed
data are given in Table 2.
Image analysis
The number of RetCam120 images taken per session and
transmitted to the Reading Centre varied widely from one
to 60 per eye (mean ten), despite the instruction given to all
examiners to take nine images per eye. One image was the
exception; it was always from the posterior pole and usually
at the first exam in very tiny infants. Image quality was
highly variable between infants with different degrees of
maturity and compliance, between the various NICUs, and
also between different examiners. In total, 3,230 image sets
(6,460 eyes) were taken, of which 97.6 % (3,151/3,230)
were of high enough quality to be evaluated as to (1) degree
of retinal maturity, (2) retina at risk for progression to STR-
ROP within 1 or 2 weeks, or (3) STR-ROP within days.
Only 2.4 % (79/3,230) of image sets could not be classified
according to these criteria; the majority of them had been
taken in the peripheral NICUs. Repeat examinations of
Table 2 Baseline characteristics of all patients screened and of
patients with ROP
Screened (n=1,222) ROP (n=337)
Gender
Male [%] 662 [54.2] 172 [51.1]
Female [%] 560 [45.8] 165 [48.9]
Birth weight (BW) n =1,215* n =335*
Mean [g] 1,395 1,047
Range [g] 410–4,780 410–2,135
SD [g] 507 313
<750 g [g] 77 [6.3] 61 [18.2]
750–999 g [%] 198 [16.3] 110 [32.8]
1,000–1,249 g [%] 215 [17.7] 82 [24.5]
1,250–1,500 g [%] 343 [28.2] 58 [17.3]
>1,500 g [%]# 382 [31.5] 24 [7.2]
Gestational age (GA) n=1,221* n=336*
Mean [wks] 30 28
Range [wks] 22–40 22–36
SD (wks) 3 2
<27 wks [%] 140 [11.5] 106 [31.6]
27–31 wks [%] 778 [63.7] 207 [61.6]
>31 wks [%] 303 [24.8] 23 [6.8]
BW and GA n=1,215 n=335
<32 wks, <1,501 g 722 [59.4%] 297 [88.7%]
<32 wks, >1,500 g 191 [15.7%] 15 [4.5%]
>31 wks, <1,501 g 111 [9.1%] 14 [4.2%]
>31 wks, >1,500 g 191 [15.7%] 9 [2.7%]
*Numbers do not correspond to the overall numbers in all instants, as
in some infants, data on BWor GA is missing (in 1 infant, both values
were lost).
#The remaining 31% had one or more other risk factors for
developing ROP
Table 3 Prevalence of ROP in dependence on GA in 335 infants
GA <36wks (all infants screened*) <26wks 26wks 27wks 28wks 29wks 30wks 31wks
Any stage of ROP 335/1,191 58/71 48/69 56/95 54/107 47/136 33/197 17/243
(28.1%) (81.7%) (69.6%) (58.9%) (50.5%) (34.6%) (16.8%) (7.0%)
STR-ROP 46/1,191 20/71 14/69 4/95 4/107 3/136 0/197 1/243
(3.9%) (28.2%) (20.3%) (4.2%) (3.7%) (2.2%) (0.0%) (0.4%)
TR-ROP 42/1,191 20/71 10/69 4/95 4/107 3/136 0/197 1/243
(3.5%) (28.2%) (14.5%) (4.2%) (3.7%) (2.2%) (0.0%) (0.4%)
Zone I 11/42 8/20 3/10 0/4 0/4 0/3 0/0 0/1
(26.2%) (40.0%) (30.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0%)
Zone II 31/42 12/20 7/10 4/4 4/4 3/3 0/0 1/1
(73.8%) (60.0%) (70.0%) (100%) (100%) (100%) (0.0%) (100%)
GA gestational age; STR-ROP suspected treatment-requiring ROP; TR-ROP treatment-requiring ROP cases are indicated in bold letters
The column <36 wks gives the total numbers of all infants screened and with documented GA. *As for some babies the gestational age was not
documented, the total number of babies examined differs in Table 2.
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not show any STR-ROP. The number of examinations per
infant ranged from one to 27 (including follow-up
examinations after treatment), and was 2.6 on average.
The number of examinations for the 46 infants with STR-
ROP ranged from four to 27, and was 4.6 on average.
ROP stages detected with the RetCam 120
Detailed ROP findings are listed in Tables 3 and 4.I nt o t a l ,
27.6% of the 1222 premature babies (337 infants) were
diagnosed with CR-ROP. Of those, 71.8% (242/337) were
mild, i.e. ROP stage 1 to 3 without plus up to mid-peripheral
zone III, 15.7% (53/337) prethreshold type-1 ROP in zone I
(according to ETROP), and 12.5% (42/337) threshold in
zone II (according to Cryo-ROP). Zone I disease was present
in 3.3% (11/337), zone II disease in 76.5% (258/337), and
zone III disease in 20.2% (68/337). Forty-six babies
developed a more severe ROP stage i.e. STR-ROP, making
a final treatment decision by a specialist BIO examination
necessary: 34 were from peripheral NICUs, and 12 from the
local NICU (Table 5). All STR-ROP stages were detected
with the RetCam120, i.e. the sensitivity was 100%, as none
of the local ophthalmologists had reported a higher stage (it
is however unknown whether the local ophthalmologists
had detected all pathology diagnosed with WFDI at the
Reading Centre). The paediatric data of the babies with
STR-ROP are listed in Table 5. Following the ETROP
classification done retrospectively for all children screened
since 2001, 95 were type-1 or type-2 ROP: 67.4% (64/95)
type-1, and 32.6% (31/95) type-2 ROP. All 12 infants from
the local NICU and 30/34 infants from the peripheral NICUs
were treated.
To evaluate the positive predictive value as to
treatment-requiring ROP (TR-ROP), only the 34 infants
with STR-ROP from the peripheral NICUs were consid-
ered. In those 34 infants, specialist BIO exams were
performed to ultimately determine the need for treatment.
Twenty-eight infants were treated at the first referral, two
infants after further follow-up examinations, and in four
STR-ROP (n=34) TR-ROP (n=30) Spontaneous regression (n=4)
Male [%] 19 [55.9] 15 [50.0] 4 [100.0]
Female [%] 15 [44.1] 15 [50.0] 0.0
Birth weight
Mean [g] 805 799 775
Range [g] 440–1,495 440–1,495 670–850
SD [g] 203 229 82
Gestational age
Mean (wks) 26 26 26
Range [wks] 22–31 22–29 26
SD (wks) 2 2 0
Table 5 Paediatric data of
infants with suspected treatment-
requiring ROP making a final
treatment decision by BIO neces-
sary (only infants screened in the
4 peripheral NICUs)
BIO binocular indirect ophtal-
moscopy; STR-ROP suspected
treatment-requiring ROP; TR-
ROP treatment-requiring ROP
Table 4 Prevalence of ROP in dependence on BW in 335 infants
BW <4,780g (all infants screened*) <750g 750 g to <1,000g 1,000g to <1,250g 1,250g to 1,500g
Any stage of ROP 335/1,215 61/77 110/198 82/215 58/343
(27.6%) (79.2%) (55.6%) (38.1%) (16.9%)
STR – ROP 46/1,215 21/77 21/198 2/215 2/343
(3.8%) (27.3%) (10.6%) (0.9%) (0.6%)
TR – ROP 42/1,215 20/77 18/198 2/215 2/343
(3.5%) (26.0%) (9.1%) (0.9%) (0.6%)
Zone I 11/42 7/20 4/18 0/2 0/2
(26.2%) (35.0%) (22.2%) (0%) (0%)
Zone II 31/42 13/20 14/18 2/2 2/2
(73.8%) (65.0%) (77.8%) (100%) (100%)
BW birth weight; STR-ROP suspected treatment requiring ROP; TR-ROP treatment-requiring ROP cases are indicated in bold letters. The column
<4780 g gives the total numbers of all infants screened and with documented birth weight. *As for some babies BW was not documented, the total
numbers of babies examined differs in Table 2
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positive predictive value for TR-ROP was 88.2%: 82.4%
at the first referral, and 88.2% at further follow-up.
Significance of evaluating the anterior segment
Starting from January 2002, imaging of the anterior
segment was added to the protocol. In all eyes with
significant ROP for which we had readable images, a
dilated persistent tunica vasculosa lentis TVL and iris
hyperaemia were always present at the time of STR-ROP.
No eye without TVL received treatment. As good quality
anterior segment images were not available for all infants,
the overall percentage of eyes with ROP and persistent
TVL, and the fraction of those that had STR-ROP could not
be evaluated. Examples of persistent TVL are shown in
Fig. 3. Imaging of the anterior segment appears important
in the assessment of STR-ROP.
Binocular indirect ophthalmoscopy (BIO) versus digital
imaging
Although both BIO and WFDI with the RetCam120 were
recommended in our study protocol, no systematic docu-
mentation of the actual number of dual examinations is
available from the NICUs outside Regensburg, nor
concerning the order of examinations, i.e. BIO first or
digital imaging first. It is noteworthy that none of the
peripheral ophthalmologists reported on higher ROP stages
with BIO compared to our results from WFDI analysis.
A subset of 41 consecutive infants (63 image sets, 125
eyes) screened in the NICU in Regensburg received dual
masked examinations; BIO from an experienced paediat-
ric ophthalmologist (HE), and WFDI from a senior
resident. The images were reevaluated in 2008 by the
senior ophthalmologist B.L. BW ranged from 560 g to
1,880 g (mean 1,357 g, SD 288 g), GA from 24–
33 weeks (mean 30 wks, SD 2 wks). The infants
received one to eight examinations (mean 1.6). Agree-
ment was found for 53 examinations, i.e. in 84%.
Disagreement was seen in ten examinations (16%); in
five examinations (8%), BIO reported a higher stage, and
in five examinations (8%), the RetCam images indicated
a higher stage. The highest stage seen in the eyes with
disagreement was stage 2, peripheral zone II, and the
largest difference was one stage in zone III. As to the
classifications no ROP, CR-ROP and STR-ROP, no
change in classification resulted in four of the ten
examinations with disagreement (6.4%); in three instan-
ces, BIO found CR-ROP (stage 1, zone II–III) compared
to no ROP with WFDI (4.8%), and in three instances,
WFDI found CR-ROP (stage 1, zone II–III) compared to
no ROP with BIO (4.8%).
Discussion
Several studies have investigated different issues for the use
of the RetCam120 in the management of ROP [32–44, 47,
48]. In an early study by Yen et al., ROP-screening with the
RetCam120 was performed by neonatal nurses in preterm
babies at risk [33, 42]. Pictures were taken only at two
points of time in the neonatal phase; at a PMA of 32–
34 weeks, and at 38–40 weeks PMA. WFDI was
considered to have an insufficient sensitivity to be
recommended as a substitute for BIO in screening for
ROP. Contrary to the WFDI, conventional BIO screening
was performed according to the actual guidelines, i.e. every
2 weeks. Roth et al. also compared conventional screening
with WFDI [34]. The sensitivity to detect stage 1 or 2 ROP
in peripheral zone II or III with RetCam120 images was
low. However, in those missed cases ROP regressed
Fig. 3 Examples of iris at the time of treatment-requiring ROP. A
Almost complete tunica vasculosa lentis with massive vessel dilatation.
B Partial tunica vasculosa lentis, clearly hyperaemic. C Only minimal
tunica vasculosa lentis. Severe engorgement of the iris vessels
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medical evaluations and recommendations of WFDI were
compared with conventional onsite evaluations and recom-
mendations, to see if the local examiner and the remote
examiner would reach the same conclusion for treatment.
All but one of the 19 eyes examined had an advanced stage
of ROP (at least prethreshold disease). They found
agreement with both methods; in one instance, plus disease
was correctly identified accurately with WFDI but not with
BIO. Following the early rather pessimistic reports by Yen
[33, 42], the same group has now published a series of
papers evaluating in detail sensitivity, specificity, positive
and negative predictive value of WFDI and telemedicine
for ROP screening [38–40]. In their paper from 2007, they
report on sensitivity for type 2 prethreshold or worse ROP
at PMA 35–37 weeks of 85.1% to 94.3% for three different,
highly experienced graders, and 100% sensitivity for all
three graders for TR-ROP, with a specificity of 80.6% to
94.1%. In this particular study, only three images were
taken as a routine, which is different from the present study.
Lately, the Photo-ROP study group has published design
issues of their trial, which included establishing the
information technology infrastructure for an ROP study
based on digital imaging, defining the study endpoints,
estimating event rates, defining a standardized imaging
protocol, and defining standards for interpretation of image
quality and clinical findings [45].
Detection of ROP with WFDI and with BIO
Our study reflects the typical population of preterm infants
that a general ophthalmologist will see in Germany as a
consultant in a NICU. Compared to some other studies using
conventional screening with BIO, the incidence of CR-ROP
(27.6%) in our total population of 1,222 premature babies
appears comparable to the reported incidence of ROP in
similarly immature babies (Table 6). When analyzing only
children with a BW<1,250 g, the incidence of CR-ROP was
51.6% (253/490), and went up to 62.2% in children with a
BW<1,000 g (171/275). These numbers are comparable to
those reported in other series [42–44]. In our work, with a
total of 1,222 babies screened between 2001 and 2006, no
incidents were noted where TR-ROP was missed with timely
RetCam120 examinations. When comparing BIO and
RetCam images results in 125 eyes from 63 consecutive
examinations screened in the NICU in Regensburg, agree-
ment between the two methods was high, at 84%.
Disagreement occurred for both BIO and WFDI reading,
reporting a higher stage with the respective method, and thus
questioning BIO as the gold standard. In the cases where
BIO reported a higher stage of ROP, the disease was in
peripheral zone III. A similar evaluation of the sensitivity
was not possible in the NICUs outside Regensburg, due to
the study design (which is certainly a limitation). However, it
appears highly unlikely that treatable disease was missed, as
all infants were followed until retinal vascularisation was
complete, i.e. reaching out to mid-peripheral zone III, or any
stage of ROP which had resolved spontaneously. Also, none
of the local ophthalmologists reported on higher stages of
CR-ROP with BIO compared to our image readings, or on
undetected ROP at later follow-up. Therefore, we conclude
that the sensitivity to detect STR-ROP was 100% in our
study, and the overall positive predictive value to detect TR-
ROP was 88.2%. This is a major achievement compared to
37% of late referrals (13/35 prematures) we had observed
between 1992 and 1997 before starting our telemedical
program using WFDI [21].
Recently, Scott et al. [44] reported their results in a larger
subset of infants questioning whether BIO should still be
considered the gold standard for ROP screening. In fact, in
an independent analysis of images from 134 eyes, two
physicians had an intraphysician agreement between BIO
and WFDI reading of 86.7% and 85.4% respectively. The
13.6% of misinterpretations were false negatives from BIO
misjudging zone I, plus disease and mild ROP, and
corroborates with our own findings. On the other hand,
Table 6 Comparative data of incidence of ROP in infants at risk detected by screening with BIO and RetCam120 imaging
Study Infants # Mean GA (wks) Mean BW (g) ROP (all stages) Method
Palmer et al. 1991 [49] 4,099 All<1,250 g ! 65.8% BIO
Larsson et al. 2002* [50] 253 28.5 1,118 36.4% BIO
Larsson et al. 2002** [51] 392 29.4 1,381 25.5% BIO
Mathew et al. 2002 [52] 205 28 1,205 31.2% BIO
Chiang et al. 2004
# [48] 10,596 Not indicated 1,420 24 % BIO
This study+ 1,222 30 1,395 27.6% RetCam120
*Born between 1998-2000, BW < 1500g, **born between 1998-2000, GA < 32 wks, # born between 1996-2000 with length of stay > 28 days;
ROP incidence in dependence on mean BW given for infants born in 2000.. + Clinical relevant ROP CR-ROP. CR-ROP includes all stages in
zone I and II as well as in central zone III. Peripheral zone III and ora serrata usually cannot be imaged with the RetCam120. The much higher
incidence of acute ROP in the Cryo-ROP study is explained by the lower gestational age. The incidence in the present study may be due to
significant improvements in neonatal care since 1991 and to the fact that in our study only CSROP was included.
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posterior ROP, as there is at least one observation that
WFDI readings only 10 minutes apart showed very
different degrees of severity [47].
STR-ROP versus RW-ROP
Ells and coworkers analysed the safety of telemedical
classification of referral-warranted ROP RW-ROP [36]. They
included all zone I disease, plus and stage 3 disease. In
contrast, we defined STR-ROP as the stage we wanted to see
referred for a BIO to take the final treatment decision. We
chose this narrower definition to avoid unnecessary referrals
as much as possible, but without increasing the risk for late
referrals. Comparing the number of eyes with RW-ROP and
with STR-ROP to eyes that finally received laser therapy in
the two series, the different referral pattern becomes clear.
Only 43.5% of eyes with RW-ROP (10/23 eyes) received
laser therapy in the study by Ells, compared to 88.2% of the
eyes with STR-ROP in the current study (30/34). The wider
definition of RW-ROP by Ells may contain a higher level of
safety. At the same time, this definition considerably lowers
the positive predictive value as to TR-ROP. A high positive
predictive value is, however, highly desirable to minimize
the number of unnecessary transferrals of prematures that are
stressful, hence potentially harmful, and also costly.
Limitations of WFDI
There is no doubt that DMFI faces limitations, just as
examination with BIO does. In agreement with other authors
[34, 35, 37], we consider image quality with the RetCam
120 to be suboptimal, in particular, for peripheral nasal zone
II and peripheral zone III. Technical improvements to
enhance image quality of peripheral retinal parts would be
highly desirable. When using additional criteria such as
degree of peripheral vessel arborisation and vessel diameter
for image assessment, we were able to limit the number of
infants whose retina could not be evaluated. We report that
only 2.4% of the imaging sessions did not have sufficient
image quality to assess the actual risk. This was not a major
problem, as repeat examination yielded images with suffi-
cient quality. In our experience, all users learned how to
image after being instructed on only a few babies. Obtaining
adequate pupillary dilation was crucial. In the case of
insufficient image quality, we ordered the exam to be
repeated within a week or less according to disease severity
and degree of maturity of the infant. At follow-up, none of
the infants with non-readable images at the initial exam
developed any relevant ROP. Very small infants can be
difficult to image peripherally; however, in most of these
tiny babies at least the posterior pole can be imaged, and this
is generally sufficient for risk assessment, if follow-up
examinations are advised until vascularisation is complete
in mid-peripheral zone III. There is also skill involved in
reading the images. The stereo view of the BIO is missing,
but is being replaced by learning to read subtle signs at the
border of vascularisation. It is essential that experts who are
familiar with both the funduscopic aspect with BIO and the
appearance with the RetCam120 read the images, in order
not to confuse stages 2 and 3 and peripheral stage 4. In this
respect we would like to emphasize the importance of
continuing to train young ophthalmologists with BIO to
diagnose acute ROP. With these precautions, WFDI is a
valuable screening tool.
Acceptance of our study by neonatologists and parents
Although no systematic survey of the acceptance has been
conducted in this study, all 15 neonatologists directly
involved in the study emphasized the advantage of having
images of the retinal changes. They also felt that WFDI and
imageevaluationattheReading Centreminimizedtheriskof
blindness in the infants. All neonatologists stated that this
outweighed the disadvantage of the longer time required for
the exam of the infants. Examination time was highly
examiner-dependent, and was only about 5 minutes per
infant in the NICU in Regensburg, where imaging was
performed by trained paediatric ophthalmologists of the
Reading Centre. In the peripheral NICUs, paediatricians
usually helped the ophthalmologists to code and collect the
images, and to transmit the coded images via ISDN (phone
line) and the coded paediatric data by fax or email. The
parents’ compliance was evaluated from their consent to
participate in the telemedicine program. Once detailed
information had been provided by the neonatologist,
virtually all parents consented to the telemedicine program.
Only parents who had consented were included in the study.
Limitations of our study
The major limitation of our study is that comparison of
WFDI and BIO was performed in only a fraction of
infants. A comparison in all infants did not appear
feasible, as in the peripheral NICUs screening was
always performed by single ophthalmologists. So it
cannot be excluded that WFDI was done after BIO,
and that therefore the examiner was biased as to the
result. A significant influence appears, however, unlikely
given the limited quality of many image sets and the fact
that BIO was—contrary to the protocol—not always
added; this was reported by the paediatricians who
helped with the examination. Bias was also minimized
as the results of the local ophthalmologist´s examination were
unknown to the readers at the Reading Centre, who based
their diagnosis exclusively on reading of the images.
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A recent study has looked into the cost-utility relationship
of telemedicine with digital imaging compared to BIO [53].
Although such an evaluation is difficult due to the
enormous complexity of factors and aspects involved, it
would appear that telemedicine can be less expensive than
BIO based on US rates of reimbursement. No formal analysis
on the cost-effectiveness of our program has been done so far.
However, given 100% sensitivity to detect STR-ROP, and
comparing this to 37% late referrals to the Department of
OphthalmologyattheUniversityofRegensburgbetween1992
and 1997, with consecutive blindness in 62% of the
infants (8/13) and unilateral blindness in 38% (5/13), the
benefit of our program, both from an economic and a
medical standpoint would appear evident. However,
caution is necessary when comparing incidence of very
advanced ROP and treatment outcome in infants from
two completely different time periods.
Conclusion
We demonstrate the use of WFDI to screen for CR-ROP
in a routine clinical telemedical setting with ophthalmol-
ogists taking the images. At present, nurses or profession-
al photographers are not using WFDI in Germany. With a
documented sensitivity of 100% to detect STR-ROP and a
positive predictive value of 88.2% for TR-ROP in a large
cohort of 913 babies in four different peripheral NICUs,
this approach is shown to be a safe and effective method
to timely detect potentially blinding ROP, and compares
favourably to the high percentage of late referrals we had
seen before starting our telemedical program. We get
support from a number of recent studies that have
compared BIO with WFDI in several studies, yet with
much smaller sample sizes. The weakness of our study is
that no formal comparison of BIO and WFDI is available
for the majority of the exams. Key to success are highly
qualified image readers that have to be experienced with
BIO as well. Beyond this, our database combining all
relevant paediatric data with serial imaging of all
prematures at risk for ROP also allows re-evaluating
classification of TR-ROP according to evolving treatment
indications, and provides an extraordinary resource for
further investigations and research.
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